PLADO for Conservative Management of CKD

Not Applicable

Recruiting

• Conditions: Chronic Kidney Disease(CKD); Metabolic Acidosis

• Registration Number: NCT06932042
• Lead Sponsor: Lebanese American University

Brief Summary

The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with CKD. It will also learn about the safety, viability, and economic attractiveness of this diet.

The main questions it aims to answer are:

* Is the PLADO diet more effective in managing metabolic acidosis in comparison with the standard-of-care CKD diet in adults with CKD?

* Is the PLADO diet safe, viable, and economically attractive adults with CKD?

Researchers will compare the PLADO diet to the standard-of-care CKD diet to see if the PLADO diet works better to decrease metabolic acidosis.

Participants will:

* Receive nutrition education of the PLADO diet or the standard-of-care CKD diet via monthly sessions for 6 months.

* Visit the clinic monthly for 6 months, then after 3 months for checkups and tests.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-28
• Status Verified: 2025-04
• Study First Submitted: 2025-04-01
• Study First Submitted QC: 2025-04-09
• Last Update Submitted: 2025-04-09
• Study First Posted: 2025-04-17
• Last Update Posted: 2025-04-17
• Primary Completion: 2026-06-30
• Study Completion: 2026-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Patients aged 18 years and above, having controlled glycemic and blood pressure parameters on treatment, with an established diagnosis of stages 3-5 CKD and an estimated GFR ≤59 ml/min/1.73 m2 stable for at least three months, and with a normal nutritional status as defined by the GLIM criteria, attending the CKD outpatient clinics at LAUMC-RH, willing to undergo the baseline screening and attend the monthly face-to-face visits at the outpatient department at LAUMC-RH.

Exclusion Criteria

• Patients with overt infection, persistent anorexia, vomiting, or diarrhea within the last month, presence of wasting diseases such as cancer, tuberculosis, liver failure, heart failure, and those with serum potassium >5.5 mEq/L during the past 6 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Metabolic acidosis assessed by PTCO2	Baseline, Monthly for 6 months, Month 9

Secondary Outcome Measures

Name	Time	Method
Body weight	Baseline, Months 3, 6, and 9	Body weight measured using a balance beam scale Unit: kg
%Weight Change	Months 3, 6, and 9	%Weight Change (to the last measurement) Unit: %
Triceps Skinfold thickness	Baseline, Months 3, 6, and 9	Triceps Skinfold thickness measured using a measuring tape and a skinfold caliper Unit: mm
Body Fat Percentage	Baseline, Months 3, 6, and 9	%Body Fat for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %
Fat Free Mass Percentage	Baseline, Months 3, 6, and 9	%Fat Free Mass for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %
Total Body Water Percentage	Baseline, Months 3, 6, and 9	%Total Body Water for edema-free patients assessed using Bioimpedance analysis (Maltron Bioscan) Unit: %
Blood Urea Nitrogen (BUN)	Baseline, Monthly for 6 months, Month 9	BUN assessed via blood test Unit: mg/dL
Estimated Glomerular Filtration Rate (eGFR)	Baseline, Monthly for 6 months, Month 9	eGFR calculated using the Cockcroft-Gault equation = (((140 - age in years) x (weight in kg)) x 1.23) / (serum creatinine in micromol/l) Unit: mL/min/1.73m²
Serum Potassium (K)	Baseline, Monthly for 6 months, Month 9	Serum K assessed via blood test Unit: mEq/L
Serum Phosphorus (P)	Baseline, Monthly for 6 months, Month 9	Serum P assessed via blood test Unit: mg/dL
C-Reactive Protein (CRP)	Baseline, Months 3, 6, and 9	Serum CRP assessed via blood test Unit: mg/L
Albumin	Baseline, Months 3, 6, and 9	Serum Albumin assessed via blood test Unit: g/dL
Hemoglobin	Baseline, Months 3, 6, and 9	Serum Hemoglobin assessed via blood test Unit: g/dL
Hematocrit	Baseline, Months 3, 6, and 9	Serum Hematocrit assessed via blood test Unit: %
Mean Corpusculum Volume (MCV)	Baseline, Months 3, 6, and 9	Average size of red blood cells assessed via blood test Unit: Femtoliter (fL)
Ferritin	Baseline, Months 3, 6, and 9	Serum Ferritin assessed via blood test Unit: ng/mL
Glycated hemoglobin A1C	Baseline, Months 3, 6, and 9	Glycated hemoglobin (A1C) measured via blood test Unit: %
Urinary microalbumin: creatinine ratio (UmACR)	Baseline, Months 3, 6, and 9	UmACR assessed via urine test Unit: mg/g creatinine
Urinary potassium excretion	Baseline, Months 3, 6, and 9	Urinary potassium excretion (spot) measured via urine test Unit: meq/L
Urinary phosphorus excretion	Baseline, Months 3, 6, and 9	Urinary phosphorus excretion (spot) measured via urine test Unit: mg/dL
Global Leadership Initiative on Malnutrition (GLIM) criteria	Baseline, Months 3, 6, and 9	GLIM criteria for the diagnosis of malnutrition. A participant is identified as malnourished when at least one phenotypic and one etiologic criterion is met. Phenotypic criteria include unintentional weight loss (\>5% within 6 months or \>10% beyond 6 months), age-specific low Body Mass Index (\< 20 kg/m2 for individuals \< 70 years old and \< 22 kg/m2 for individuals 70 years and older), and reduced muscle mass assessed using body composition parameters to detect muscle depletion. Etiologic criteria include reduced food intake or assimilation (defined as a reduction in energy intake \> 50% of requirements for over one week or any reduction lasting more than 2 weeks) and the presence of acute disease or chronic diseases related inflammation.; Score: one phenotypic criterion and one etiologic criterion, to diagnose malnutrition
Total Caloric intake per kilogram body weight (Kcal/kg)	Baseline, Months 3, 6, and 9	The total caloric intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total caloric intake (Kcal) will then be divided by the body weight (kg) at the same time point of data collection.; Unit: Kcal/kg
Total dietary protein intake per kilogram body weight (g/kg)	Baseline, Months 3, 6, and 9	The total dietary protein intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of dietary proteins in grams (g) will then be divided by the dry body weight (kg) at the same time point of data collection.; Unit: g/kg
Carbohydrate intake percentage (%)	Baseline, Months 3, 6, and 9	The total carbohydrate intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of carbohydrate in grams (g) will then be multiplied by 4 Kcal to get the calories of carbohydrates. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.; Unit: percentage (%)
Total fat intake percentage (%)	Baseline, Months 3, 6, and 9	The total fat intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of fat in grams (g) will then be multiplied by 9 Kcal to get the calories of fat. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.; Unit: percentage (%)
Trans fat intake percentage (%)	Baseline, Months 3, 6, and 9	The total trans-fat intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend). The estimated total amount of trans-fat in grams (g) will then be multiplied by 9 Kcal to get the calories of fat. Afterwards, it will be divided by the total amount of calories consumed at the same time point of data collection to obtain the percentage of total intake.; Unit: percentage (%)
Total potassium intake (g)	Baseline, Months 3, 6, and 9	The total potassium intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.; Unit: g/d
Total phosphorus intake (g)	Baseline, Months 3, 6, and 9	The total phosphorus intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.; Unit: g/d
Total sodium intake (g)	Baseline, Months 3, 6, and 9	The total sodium intake will be assessed using a culturally specific quantitative Food Frequency Questionnaire (FFQ) crossed-checked with 24-hour recall series (one on a weekday and one on a weekend) and reported in grams per day.; Unit: g/d
Nutrition focused physical examination (NFPE)	Baseline, Months 3, 6, and 9	The nutrition focused physical examination will be conducted by a licensed dietitian who will assess fat and muscle depletion, as well as the presence of edema.
Muscle strength (kg)	Baseline, Months 3, 6, and 9	Muscle strength will be measured using a handgrip strength assessment with a calibrated hand dynamometer. Participants will be seated upright with their back supported, feet flat on the floor, and their elbow flexed at a 90-degree angle. The hand dynamometer will be adjusted to fit the participant's hand size who will be instructed to squeeze the dynamometer with maximum effort for 3-5 seconds. Three measurements will be taken for each hand, with a rest period of 30 to 60 seconds and the average of the three measurements will be recorded as the final handgrip strength.; Unit: kg
Gastrointestinal Symptoms	Baseline, Monthly for 6 months, Month 9	Gastrointestinal symptoms will be assessed using the Birmingham IBS Symptom Questionnaire (B-IBS-Q), a validated tool for evaluating the frequency, severity, and impact of gastrointestinal symptoms. It is a self-administered questionnaire consisting of 11 items designed to assess the frequency of IBS-related symptoms, with each question having a standard response scale. Symptoms are measured based on a 6-point Likert scale (0-5) ranging from all of the time (5) to none (0) and converted to 100, with higher scores indicating more frequent IBS symptoms. The scale has 3 dimensions, including pain, constipation, and diarrhea.
Health-related Quality of Life	Baseline, Months 3, 6, and 9	Quality of life will be assessed using the EuroQOL-5D-5L (EQ-5D-5L), a widely validated and internationally recognized instrument for measuring health-related quality of life. The tool consists of two components: a descriptive system and a visual analog scale (VAS). The descriptive component includes five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale, ranging from no problems to extreme problems. Participants will select the most appropriate level that reflects their current health status for each dimension. The responses are then used to generate a health state profile, which can be converted into a single index score using country-specific value sets. In addition to the descriptive system, participants will rate their overall health status using a visual analog scale (VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health).
Costs	Baseline, Months 3, 6, and 9	Costs relevant to direct medical costs, direct non-medical costs, and indirect costs assessed using a resource utilization questionnaire with the patients, and calculated following the identification, measurement, and valuation steps.

Trial Locations

Locations (1)

Lebanese American University Medical Center- Rizk Hospital; 🇱🇧 Beirut, Lebanon